314 related articles for article (PubMed ID: 35299868)
1. Identification of IL20RB as a Novel Prognostic and Therapeutic Biomarker in Clear Cell Renal Cell Carcinoma.
Guo H; Jiang S; Sun H; Shi B; Li Y; Zhou N; Zhang D; Guo H
Dis Markers; 2022; 2022():9443407. PubMed ID: 35299868
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma.
Zhang H; Liu Y; Wang B; Wang C
BMC Genom Data; 2022 Jul; 23(1):58. PubMed ID: 35883015
[TBL] [Abstract][Full Text] [Related]
3. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration.
Zhang F; Yuan D; Song J; Chen W; Wang W; Zhu G; Hu B; Chen X; Zhu J
Int Immunopharmacol; 2021 Oct; 99():107899. PubMed ID: 34217993
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma.
Huang S; Hou Y; Hu M; Hu J; Liu X
BMC Cancer; 2022 Sep; 22(1):995. PubMed ID: 36123627
[TBL] [Abstract][Full Text] [Related]
5. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
6. Wiskott-Aldrich syndrome gene as a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma.
Ding G; Wang T; Liu S; Zhou Z; Ma J; Wu J
Front Immunol; 2023; 14():1102824. PubMed ID: 37122750
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Immune Infiltration Signatures of GIMAP Family Genes in Clear Cell Renal Cell Carcinoma.
Zhang M; Zhang X; Hou J; Liang X; Zhang M
Front Biosci (Landmark Ed); 2023 Nov; 28(11):308. PubMed ID: 38062816
[TBL] [Abstract][Full Text] [Related]
8. The value of EYA1/3/4 in clear cell renal cell carcinoma: a study from multiple databases.
Liu T; Nie J; Zhang X; Deng X; Fu B
Sci Rep; 2023 May; 13(1):7442. PubMed ID: 37156847
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of
Wang T; Xie F; Li YH; Liang B
Future Oncol; 2021 Dec; 17(36):5033-5044. PubMed ID: 34704468
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Clear Cell Renal Cell Carcinoma.
Zhang C; Cui Y; Wang G; Zhao W; Zhao H; Huang X; Zhang M; Li W
J Healthc Eng; 2021; 2021():5790416. PubMed ID: 34531966
[TBL] [Abstract][Full Text] [Related]
11. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma.
Li P; Liu J; Li J; Liu P
Mol Biol Rep; 2019 Aug; 46(4):4377-4383. PubMed ID: 31147860
[TBL] [Abstract][Full Text] [Related]
13. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
14. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
15. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
[TBL] [Abstract][Full Text] [Related]
16. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
[TBL] [Abstract][Full Text] [Related]
17. Integrative analysis of TRPV family to prognosis and immune infiltration in renal clear cell carcinoma.
Gong Z; Xie J; Chen L; Tang Q; Hu Y; Xu A; Wang Z
Channels (Austin); 2022 Dec; 16(1):84-96. PubMed ID: 35389815
[TBL] [Abstract][Full Text] [Related]
18. Microenvironment-associated gene HSD11B1 may serve as a prognostic biomarker in clear cell renal cell carcinoma: a study based on TCGA, RT‑qPCR, Western blotting, and immunohistochemistry.
Han D; Yu Z; Zhang H; Liu H; Wang B; Qian D
Bioengineered; 2021 Dec; 12(2):10891-10904. PubMed ID: 34845968
[TBL] [Abstract][Full Text] [Related]
19. SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.
Xu Z; Wu Y; Fu G; Chen X; Sun J; Tian J; Jiang P; Wang Y; Jin B
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108666
[TBL] [Abstract][Full Text] [Related]
20. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]